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Introduction​:​ ​​Dynamic​ ​Aphasia​ ​(DA)​ ​is​ ​a​ ​rare​ ​form​ ​of​ ​language​ ​disorder​ ​characterized​ ​by​ ​reduced​ ​spontaneous 
speech​ ​with​ ​preservation​ ​of​ ​other​ ​language​ ​functions.​ ​Two​ ​types​ ​of​ ​DA​ ​have​ ​been​ ​described:​ ​language-specific 
type​ ​(type​ ​I​ ​DA)​ ​and​ ​domain-general​ ​type​ ​(type​ ​II​ ​DA).​ ​In​ ​type​ ​I​ ​DA,​ ​deficits​ ​are​ ​selective​ ​for​ ​word​ ​and​ ​sentence 
generation,​ ​whereas​ ​in​ ​type​ ​II​ ​DA​ ​impairments​ ​affect​ ​discourse​ ​generation,​ ​narrative,​ ​fluency,​ ​and​ ​non-verbal 
generation​ ​tasks.​ ​There​ ​is​ ​little​ ​information​ ​on​ ​the​ ​treatment​ ​of​ ​DA.​ ​Although​ ​treatment​ ​with​ ​a​ ​cognitive 
enhancing​ ​drug​ ​(bromocriptine)​ ​improved​ ​outcome​ ​in​ ​previous​ ​studies,​ ​pharmacological​ ​interventions​ ​combining 
two​ ​drugs​ ​acting​ ​on​ ​other​ ​neurotransmitter​ ​systems​ ​in​ ​DA​ ​have​ ​not​ ​been​ ​reported​ ​so​ ​far.  
Methods​:​ ​​We​ ​report​ ​an​ ​open-label​ ​pharmacological​ ​single​ ​case​ ​study​ ​(n​ ​=​ ​1)​ ​in​ ​a​ ​male​ ​patient​ ​with​ ​a​ ​chronic 
type​ ​I/II​ ​DA​ ​secondary​ ​to​ ​an​ ​ischemic​ ​infarction​ ​in​ ​the​ ​left​ ​fronto-opercular​ ​and​ ​insular​ ​regions.​ ​After​ ​baseline 
evaluation,​ ​the​ ​patient​ ​received​ ​donepezil​ ​5​ ​mg/day​ ​(2​ ​months),​ ​donepezil​ ​10​ ​mg/day​ ​(2​ ​months),​ ​donepezil​ ​10 
mg/day​ ​plus​ ​memantine​ ​20​ ​mg/day​ ​(4½​ ​months)​ ​followed​ ​by​ ​a​ ​washout​ ​period​ ​(1½​ ​months).​ ​No​ ​speech-language 
therapy​ ​was​ ​used.​ ​A​ ​comprehensive​ ​cognitive​ ​and​ ​language​ ​evaluation​ ​was​ ​carried​ ​out​ ​at​ ​baseline​ ​and​ ​at 
different​ ​endpoints.​ ​18FDG-PET​ ​was​ ​performed​ ​at​ ​the​ ​four​ ​timepoints. 
Results​:​ ​​Donepezil​ ​(5​ ​mg/day)​ ​significantly​ ​improved​ ​type​ ​I​ ​DA​ ​features​ ​(normalization​ ​of​ ​verbs​ ​generation,​ ​p​ ​= 
0.01),​ ​whereas​ ​donepezil​ ​(10​ ​mg/day)​ ​improved​ ​some​ ​type​ ​II​ ​features​ ​(normalizing​ ​spontaneous​ ​speech,​ ​verbal 
fluency​ ​and​ ​improving​ ​generation​ ​of​ ​novel​ ​thoughts,​ ​p​ ​=​ ​0.004),​ ​along​ ​with​ ​improvement​ ​of​ ​executive-attentional 
functioning.​ ​Combined​ ​therapy​ ​further​ ​enhanced​ ​cognitive​ ​function,​ ​but​ ​did​ ​not​ ​additionally​ ​improved​ ​DA.​ ​18 
FDG-PET​ ​revealed​ ​significant​ ​reductions​ ​of​ ​perilesional​ ​hypometabolic​ ​activity​ ​mainly​ ​after​ ​donepezil​ ​(10 
mg/day)​ ​and​ ​washout. 
Discussion​:​Treatment​ ​with​ ​donepezil​ ​improved​ ​language​ ​deficits​ ​in​ ​a​ ​patient​ ​with​ ​chronic​ ​post-stroke​ ​type​ ​I/II 
DA.​ ​Combined​ ​therapy​ ​(donepezil​ ​plus​ ​memantine)​ ​further​ ​enhanced​ ​executive-attentional​ ​functioning.​ ​Beneficial 
changes​ ​were​ ​associated​ ​with​ ​improvements​ ​in​ ​perilesional​ ​metabolic​ ​activity. 
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